Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease

Background. Antitumor necrosis factor (anti-TNF) therapy is a highly effective but costly treatment for inflammatory bowel disease (IBD). Methods. We conducted a retrospective cohort study of IBD patients who were prescribed anti-TNF therapy (2007–2014) in Ontario. We assessed if the insurance type...

Descripción completa

Detalles Bibliográficos
Autores principales: Rumman, Amir, Candia, Roberto, Sam, Justina J., Croitoru, Kenneth, Silverberg, Mark S., Steinhart, A. Hillary, Nguyen, Geoffrey C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292380/
https://www.ncbi.nlm.nih.gov/pubmed/28239601
http://dx.doi.org/10.1155/2017/7365937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292380/
https://www.ncbi.nlm.nih.gov/pubmed/28239601
http://dx.doi.org/10.1155/2017/7365937

Ejemplares similares